TORONTO, April 2 /PRNewswire/ -- Dyadem, the market leader in Quality Lifecycle Management and Risk Lifecycle Management solutions, has announced that Wyeth, a global leader in prescription pharmaceuticals and non-prescription consumer health care products, is using software from Dyadem to enhance and standardize its risk assessments. Dyadem's PHA-Pro, a software solution that identifies, measures and mitigates risk, enables Wyeth to set a new standard in safety for its pharmaceutical products. Wyeth's industry-leading pharmaceutical and health care products improve lives and deliver outstanding value to customers and shareholders by leading the world in innovation through pharmaceutical, biotech and vaccine technologies.
PHA-Pro is a software solution that delivers industry-standard Process Hazard Analysis (PHA) capabilities for the process industries. The PHA methodology is an integral part of a pharmaceutical manufacturer's Process Safety Management program and results in safer and more predictable production processes. Dyadem's PHA-Pro helps manage Risk Lifecycle Management processes, and was built to reflect the risk mitigation initiatives and operating environments of the various process industries. This is essential to optimizing work time, minimizing work stoppages, and reducing the potential for undesirable events, while improving the safety and quality of a given product for consumers.
With PHA-Pro being used across their global organization, Wyeth has integrated the knowledge and expertise of all departments into their PHA studies and provided the Environmental Health and Safety department visibility into the overall business process, making everyone at the company more aware of their global business and safety strategy. "We needed a systematic, methodical way to document our PHA studies," said Steven Meszaros, Corporate Director, EHS (Environmental Health and Safety), Wyeth. "With Dyadem's PHA-Pro, Wyeth has been able to establish a community of users and a standardized approach to our PHA studies. It has allowed us to create a benchmark for safety and quality for our company, which will ultimately benefit our customers."
Having used PHA-Pro for many years, Wyeth has been able to continuously improve their risk management program. The easy configuration of templates, along with the application's industry-specific libraries and report-generating features have allowed Wyeth to focus on their business process and overall business strategy, instead of worrying about the consistency of their PHA studies. Since implementing PHA-Pro, Wyeth has been able to establish a best-practice platform which has proven to management the value of a consistent hazard review process across the network.
"Wyeth's commitment to safety and visibility for all departments are some of the reasons it has remained a leader in the pharmaceutical industry," said Kevin North, President and CEO of Dyadem. "Pharmaceutical companies have traditionally had challenges ensuring consistency and accuracy in their risk assessments, but with our Risk Lifecycle Management solutions, we have given the industry a chance to address this. Wyeth shows how important it is to standardize risk mitigation initiatives, and provide an avenue for input from all areas of a business. Through their commitment to product safety, Wyeth proves how easy it is to create safe, quality products and still be on the leading edge of innovation."
Dyadem is the market leader in Quality Lifecycle Management and Risk Lifecycle Management solutions. Dyadem provides software and services that empower companies to manage quality, mitigate risks, achieve regulatory compliance, plan for business continuity and improve profitability. Dyadem works with 85% of the Fortune 500 companies and serves the high tech & electronics, medical devices, oil and gas, chemical, automotive, pharmaceutical and aerospace and defense industries. For more information, visit www.dyadem.com
Wyeth is a global leader in prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health. Wyeth's products are sold in more than 145 countries, and its product portfolio includes innovative treatments across a wide range of therapeutic areas. Wyeth's worldwide resources include 47,500 employees, manufacturing facilities on four continents, and a unique research and technology base encompassing small molecules, biopharmaceuticals, genetic engineering that will give us the next wave of innovative therapies, and vaccines. With this depth of resources, Wyeth will continue to lead the way in the development of novel therapies that address critical global health needs. For more information, visit www.wyeth.com.
For further information, contact: Text 100 Public Relations Kevin Doak 617.399.4931 email@example.com
Copyright©2009 PR Newswire.
All rights reserved